As of 2026-03-05, the Intrinsic Value of Redwood Pharma AB (REDW.ST) is -25.62 SEK. This REDW.ST valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.18 SEK, the upside of Redwood Pharma AB is -2,261.64%.
Based on its market price of 1.18 SEK and our intrinsic valuation, Redwood Pharma AB (REDW.ST) is overvalued by 2,261.64%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -25.62 - -25.62 | -25.62 | -2,261.64% |
| P/E | (45.29) - (116.60) | (89.01) | -7611.7% |
| DDM - Stable | (98.74) - 911.04 | 406.15 | 34174.4% |
| DDM - Multi | (101.29) - 732.80 | (236.35) | -20044.8% |
| Market Cap (mil) | 3.15 |
| Beta | -1.87 |
| Outstanding shares (mil) | 2.65 |
| Enterprise Value (mil) | 2.33 |
| Market risk premium | 5.10% |
| Cost of Equity | 5.56% |
| Cost of Debt | 5.00% |
| WACC | 4.76% |